Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism

We recently found that patients with drug-induced parkinsonism (DIP) may have normal (group I) or abnormal (group II) putamen [I-123]FP-CIT DAT (dopamine transporter) binding. In this study we reassessed clinical features and DAT binding in 19 of the original 32 patients (10 of group I and 9 of group II) after a 19-39-month follow-up period and tested the effects of chronic levodopa treatment in both cohorts of patients. In group I patients, [I-123]FP-CIT SPET (single photon emission tomography) was still normal in all patients at follow-up; DAT binding and UPDRS (Unified Parkinson's Disease Rating Scale) motor score values did not differ from baseline. In group II patients, [I-123]FP-CIT SPET was still abnormal at follow-up; putamen DAT binding was significantly reduced and UPDRS III score higher compared to baseline. Levodopa treatment improved motor symptoms in three out of ten patients of group I and in eight out of nine patients of group II. No adverse psychiatric effects were observed in any of the patients. This study shows that DAT binding imaging may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals in the context of a progressive degenerative parkinsonism. Patients with DIP may benefit from levodopa therapy, particularly when dopamine nerve terminal defects are present, and this should be considered in the therapeutic management of these patients

Antimicrobial antibodies in patients with a non-specific arthritis

[No abstract available

Antimicrobial antibodies in patients with a non-specific arthritis

[No abstract available

[123I]FP-CIT SPET imaging in drug-induced Parkinsonism

We assessed the status of dopamine nerve terminals in patients treated with dopamine receptor blocking agents (DRBAs) who had developed drug-induced parkinsonism (DIP). We performed [(123)I]FP-CIT SPET in 32 consecutive patients who were on DRBAs for at least 6 months and developed extrapyramidal signs. The UPDRS-III was used to assess clinical severity. Twenty-six age- and sex-matched healthy subjects served as control group. Putamen [(123)I]FP-CIT SPET binding was reduced in 14 and normal in the remaining 18 patients. There was no difference between the two groups for age, duration of DRBAs treatment, UPDRS III, tremor, rigidity, and bradykinesia subscores for upper and lower limbs. Conversely, symmetry of parkinsonian signs and presence bucco-linguo-masticatory dyskinesias were more frequent in individuals with normal tracer binding. Imaging of the dopamine transporter may help to identify subjects with DIP secondary to a loss of dopamine nerve terminals. (c) 2008 Movement Disorder Society

Comparative analysis of visual and semi-quantitative assessment of striatal [123I]FP-CIT-SPET binding in Parkinson's disease

We used qualitative visual assessment and semiquantitative measures of striatal DAT binding using [(123)I]FP-CIT-SPET in 85 patients with Parkinson's disease (PD). We compared these two assessments and their correlation with PD clinical progression. SPET imaging was visually classified by a nuclear medicine physician as normal or abnormal pattern grade I, II and III, in relation to a different degree of radioligand reduction uptake. Nineteen patients presented abnormal grade I (group 1), 53 grade II (group 2) and 13 grade III (group 3). The UPDRS III motor score, the H-Y score, the rigidity and bradykinesia subscores were significantly different among the three groups. Post hoc analysis showed that all values of these clinical parameters were higher in group 3 than in 2 and 1. All clinical indices were also significantly higher in group 2 than in group 1. This means that groups 3 and 2 were clinically more severely affected. No significant differences among the 3 groups were observed for age or duration of disease. Values of the mean striatum uptake were also significantly different among the three groups. Post hoc analysis revealed significantly lower values of the mean striatum uptake in group 3 with respect to groups 2 and 1; values were also significantly lower in group 2 than in group 1. We conclude that our findings of good consistency between visual and semi-quantitative assessment may help simplify the evaluation of striatal DAT binding in PD in a clinical routine setting

The second generation VLT instrument MUSE: Science drivers and instrument design

The Multi Unit Spectroscopic Explorer (MUSE) is a second generation VLT panoramic integral-field spectrograph operating in the visible wavelength range. MUSE has a field of 1x1 arcmin(2) sampled at 0.20.2 arcsec(2) and is assisted by a ground layer adaptive optics system using four laser guide stars. The simultaneous spectral range is 0.465-0.93 mum, at a resolution of Rsimilar to3000. MUSE couples the discovery potential of a large imaging device to the measuring capabilities of a high-quality spectrograph, while taking advantage of the increased spatial resolution provided by adaptive optics. This makes MUSE a unique and tremendously powerful instrument for discovering and characterizing objects that lie beyond the reach of even the deepest imaging surveys. MUSE has also a high spatial resolution mode with 7.5x7.5 arcsec(2) field of view sampled at 25 milli-arcsec. In this mode MUSE should be able to get diffraction limited data-cube in the 0.6-1 mum wavelength range. Although MUSE design has been optimized for the study of galaxy formation and evolution, it has a wide range of possible applications; e.g. monitoring of outer planets atmosphere, young stellar objects environment, supermassive black holes and active nuclei in nearby galaxies or massive spectroscopic survey of stellar fields